Isolagen, Inc. has completed injections in the pivotal phase III clinical trials evaluating the Isolagen Therapy for the treatment of nasolabial folds, or wrinkles (Studies IT-A-005 and IT-A-006). As a result, subjects have advanced to the follow-up period of the study. The study was a multi-centre, double-blind, randomised and placebo-controlled one.

Also, the company has completed injections in the phase II open label study designed to gather further safety and potential application information on the use of Isolagen Therapy for the full face (Study IT-A-007). The subjects in this study also have advanced to the follow-up period.

"These are important clinical milestones to Isolagen, especially the advancement of our lead phase III pivotal wrinkle study to the follow-up period of the trial," said Declan Daly, chief executive officer, Isolagen, Inc.

Isolagen, Inc. is an aesthetic and therapeutic company committed to developing and commercialising scientific advances and innovative technologies.